

### In the Claims

1. (Cancelled)

2. (Currently Amended) A process of preparing a controlled release oral dosage form comprising:

(a) mixing an active pharmaceutical ingredient selected from the group consisting of morphine, hydromorphone, codeine, oxymorphone, ~~nal-buphine~~, nalbuphine, hydrocodone, dihydrocodeine, dihydromorphine, buprenorphine, oxycodone, ~~naltrex-one~~, naltrexone, naloxone, and pharmaceutically acceptable salts thereof and an acrylic polymer to yield a mixture;

(b) forming said mixture into a solid unit dosage form, and

(c) curing said solid unit dosage form.

3-8 (Cancelled)

9. (Previously Presented) A process of preparing a controlled release oral dosage form comprising:

(a) mixing oxycodone and ammonio methacrylate copolymer to yield a mixture;

(b) forming said mixture into a tablet using dry granulation or direct compression;

and

(c) curing said tablet for a time and at a temperature sufficient such that a Differential Scanning Calorimetry (DSC) scan will produce no significant peaks in the region of from about 40° C to about 70° C.

10. – 15. (Cancelled)

16. (Previously Presented) A process of preparing a controlled release oral dosage form comprising:

- (a) mixing an opioid active pharmaceutical ingredient and an acrylic polymer to yield a mixture;
- (b) forming said mixture into a solid unit dosage form, and
- (c) curing said solid unit dosage form.